Ann: Notice of Extraordinary General Meeting/Proxy Form, page-262

The RAD placement and possible CR afterwards to reach the $65m is an 180 degree turn. The first $15m go the a pharma cornerstone investor, something IMU and CHM are missing. Now that he pulled this one off there is hope he himself or someone else got his head finally turned in the right direction.

Now my speculation gets a bit more substance as I have speculated about the possibly new employer of JC could make a move. She knows all about CDH17 and if that is really a big thing then there will be some offers of any kind. What a set up that would be.

But why using the CR-Sharks Lind and Bell Potter before that if there are better ways which some and I always have suggested.

RM worked for Amgen and IMU is using Amgens CD19 compound for one of its CF33 trials. Maybe we hear from them next time?

GLTA